No Data Yet
Biotechnology firm Sensorion announced it will present at a January 2026 healthcare conference, as its stock ALSEN.PA fell 4.93%.
Embecta Corp. announced it will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
JP Morgan upgraded Edwards Lifesciences (EW) from Neutral to Overweight on December 18, 2025, with an average analyst price target suggesting a 13.00% upside.
Biotechnology company Kallyope will present updates on its migraine and obesity drug pipeline at the J.P. Morgan Healthcare Conference on January 13, 2026.
JPMorgan reduced its price target for Wolters Kluwer to €105, even as the company completed a €1.0 billion share buyback.
Acadia Pharmaceuticals announced its CEO will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, to discuss the company's clinical pipeline.
Arcus Biosciences announced its CEO, Terry Rosen, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
JPMorgan's 2026 outlook signals a market shift from AI hype to profitability after a PwC survey found only one-third of over 4,700 CEOs saw expected financial gains from GenAI in 2025.
JP Morgan downgraded Realty Income (O) to Underweight, forecasting a 24.29% decrease in the company's annual revenue.
JP Morgan downgraded Welltower (WELL) from Overweight to Neutral on December 18, 2025, as projected annual revenue is expected to decrease by 25.33%.
S&P 500 companies increased share buybacks by 6.2% to $249.0 billion in Q3 2025, reaching a record $1.020 trillion for the 12 months ending in September.
US Financial 15 Split Corp. declared a monthly preferred share dividend of $0.07075, representing a 10.00% annual yield, payable on January 9, 2026.
An analysis on December 17, 2025, identified JPMorgan Chase (JPM), Tapestry (TPR), and The Hartford (HIG) as underperformers, citing JPMorgan's weak 2.6% net interest margin and a projected 22.5% sales decline for The Hartford.
Service Compression increased its asset-based loan facility by $100 million to a new total of $400 million to fund fleet growth and technology investments.
Postal Realty Trust's fair value estimate increased by 7.6% to $17.93 per share, driven by upgraded forecasts for rental income and cash flow visibility.
A UK court dismissed a $3.2 billion lawsuit against major banks, including JPMorgan, UBS, and Citigroup, for alleged foreign exchange rigging on December 18, 2025.
BNP Paribas announced on December 18, 2025, that no stabilization actions were required for Zenita's (Maticmind SPA) €375 million, 7-year bond offering, indicating strong investor demand.
Calyxo, Inc. announced it will present its CVAC kidney stone treatment system at the J.P. Morgan Healthcare Conference on January 12, 2026, targeting a market projected to reach $4.1 billion by 2030.
Animal health leader Zoetis announced its CEO and CFO will present the company's strategy at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
JPMorgan warns that "extreme crowding" in speculative growth stocks like Broadcom, which has fallen over 21%, creates high risk for a sharp market reversal.